Insider · CIK 0001651281

SCHEIBLER LUKAS

Reports to the SEC for 2 companies · SEATTLE, WA

sec.gov

Transactions

Companies

Filings

CIK

0001651281

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-12-01	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−10K sh	$60.00	−$600K	68,299
2023-12-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−10K sh	—	—	39,391
2023-12-01	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+10K sh	$13.85	+$139K	78,299
2023-09-06	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−1,756 sh	$43.01	−$75.5K	68,299
2023-02-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Research Officer	AAward	+14K sh	—	—	14,023
2023-02-21	APLSApellis Pharmaceuticals, Inc.A Award	Chief Research Officer	AAward	+9,886 sh	—	—	70,358
2023-02-21	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Research Officer	FTax Payment	−715 sh	$58.50	−$41.8K	69,643
2023-02-10	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Research Officer	FTax Payment	−678 sh	$51.21	−$34.7K	60,472
2023-01-27	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Research Officer	FTax Payment	−542 sh	$52.77	−$28.6K	61,150
2023-01-20	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Research Officer	FTax Payment	−2,015 sh	$52.05	−$105K	61,692
2023-01-12	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Research Officer	AAward	+35.5K sh	$52.66	+$1.87M	35,472
2023-01-12	APLSApellis Pharmaceuticals, Inc.A Award	Chief Research Officer	AAward	+22.6K sh	—	—	63,707
2022-05-27	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−10K sh	$43.00	−$430K	40,358
2022-04-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)J Other	Chief Research Officer	JOther	−11.3K sh	—	—	0
2022-04-21	APLSApellis Pharmaceuticals, Inc.J Other	Chief Research Officer	JOther	−1,875 sh	—	—	50,358
2022-04-05	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−609 sh	—	—	49,391
2022-04-05	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+609 sh	$13.85	+$8,434.65	52,842
2022-04-05	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−609 sh	$60.09	−$36.6K	52,233
2022-04-04	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−818 sh	$55.84	−$45.7K	54,919
2022-04-04	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+3,504 sh	$13.85	+$48.5K	55,737
2022-04-04	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−1,249 sh	$57.80	−$72.2K	52,233
2022-04-04	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−3,504 sh	—	—	50,000
2022-04-04	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−1,437 sh	$56.86	−$81.7K	53,482
2022-04-01	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−11.5K sh	$55.05	−$633K	52,233
2022-04-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−11.5K sh	—	—	53,504
2022-04-01	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+11.5K sh	$13.85	+$159K	63,729
2022-02-14	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+720 sh	$26.73	+$19.2K	52,233
2022-02-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−720 sh	—	—	133,777
2022-02-11	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−1,666 sh	$46.80	−$78K	51,513
2022-02-10	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+10K sh	$13.85	+$139K	63,179
2022-02-10	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−10K sh	—	—	65,000
2022-02-10	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Research Officer	FTax Payment	−678 sh	$47.12	−$31.9K	53,179
2022-02-10	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−10K sh	$50.00	−$500K	53,179
2022-02-08	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−10K sh	—	—	75,000
2022-02-08	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+10K sh	$13.85	+$139K	63,857
2022-02-08	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−10K sh	$45.00	−$450K	53,857
2022-01-31	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−1,233 sh	$38.47	−$47.4K	53,857
2022-01-28	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Research Officer	FTax Payment	−642 sh	$38.59	−$24.8K	55,090
2022-01-21	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+3,021 sh	$26.73	+$80.8K	29,681
2022-01-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−3,021 sh	—	—	134,497
2022-01-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Research Officer	AAward	+37K sh	—	—	36,951
2022-01-21	APLSApellis Pharmaceuticals, Inc.A Award	Chief Research Officer	AAward	+26.1K sh	—	—	55,732
2021-06-10	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Research Officer	SSale	−3,417 sh	$60.00	−$205K	26,651
2021-02-10	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Research Officer	FTax Payment	−680 sh	$47.72	−$32.4K	29,290
2021-01-28	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Research Officer	AAward	+11.3K sh	—	—	11,250
2021-01-28	APLSApellis Pharmaceuticals, Inc.A Award	Chief Research Officer	AAward	+7,500 sh	—	—	28,095
2021-01-28	APLSApellis Pharmaceuticals, Inc.A Award	Chief Research Officer	AAward	+1,875 sh	—	—	29,970
2021-01-28	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Research Officer	AAward	+45K sh	—	—	45,000
2020-12-08	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	−7,482 sh	—	—	137,518
2020-12-08	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Chief Research Officer	MExercise/Conversion	+7,482 sh	$26.73	+$200K	20,595

Recent filings

Accepted (ET)
Dec 54
SCHEIBLER LUKAS0001127602-23-028966
SEC(opens sec.gov)
Sep 74
SCHEIBLER LUKAS0001127602-23-023845
SEC(opens sec.gov)
Feb 224
SCHEIBLER LUKAS0000899243-23-005789
SEC(opens sec.gov)
Feb 144
SCHEIBLER LUKAS0001127602-23-005162
SEC(opens sec.gov)
Jan 304
SCHEIBLER LUKAS0001127602-23-002688
SEC(opens sec.gov)
Jan 244
SCHEIBLER LUKAS0001127602-23-002135
SEC(opens sec.gov)
Jan 174
SCHEIBLER LUKAS0001127602-23-001500
SEC(opens sec.gov)
May 314
SCHEIBLER LUKAS0001127602-22-016013
SEC(opens sec.gov)
Apr 64
SCHEIBLER LUKAS0001127602-22-011670
SEC(opens sec.gov)
Apr 54
SCHEIBLER LUKAS0001127602-22-011526
SEC(opens sec.gov)

Companies

Address

C/O ACUCELA INC. 1301 SECOND AVE., SUITE 4200

SEATTLE, WA, 98101